Design of Plasmodium vivax Hypoxanthine-Guanine Phosphoribosyltransferase Inhibitors as Potential Antimalarial Therapeutics.
Keough, D.T., Rejman, D., Pohl, R., Zbornikova, E., Hockova, D., Croll, T., Edstein, M.D., Birrell, G.W., Chavchich, M., Naesens, L.M.J., Pierens, G.K., Brereton, I.M., Guddat, L.W.(2018) ACS Chem Biol 13: 82-90
- PubMed: 29161011 
- DOI: 10.1021/acschembio.7b00916
- Primary Citation of Related Structures:  
5HIA, 6BNJ, 6BO7 - PubMed Abstract: 
Plasmodium falciparum (Pf) and Plasmodium vivax (Pv) are the foremost causative agents of malaria. Due to the development of resistance to current antimalarial medications, new drugs for this parasitic disease need to be discovered. The activity of hypoxanthine-guanine-[xanthine]-phosphoribosyltransferase, HG[X]PRT, is reported to be essential for the growth of both of these parasites, making it an excellent target for antimalarial drug discovery ...